Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination

Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to enhance the priming and effector phases of the antitumor T-cell response rendering it an at...

Full description

Saved in:
Bibliographic Details
Published in:Journal for Immunotherapy of Cancer 2018-06, Vol.6 (1), p.46-17, Article 46
Main Authors: Gong, Jun, Le, Thang Q, Massarelli, Erminia, Hendifar, Andrew E, Tuli, Richard
Format: Article
Language:English
Subjects:
Animals
Antigens
Antitumor
Apoptosis
Cancer
Care and treatment
Clinical trials
Combined Modality Therapy - methods
Cytotoxicity
Disease Models, Animal
FDA approval
Health aspects
Humans
Immunization
Immunotherapy
Ionizing radiation
Ligands
Melanoma
Metastasis
Mice
Multiple myeloma
Neoplasms - drug therapy
Neoplasms - radiotherapy
PD-1
PD-L1
Preclinical
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Radiation therapy
Radiotherapy
Radiotherapy - methods
Review
T cells
Tumors
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to enhance the priming and effector phases of the antitumor T-cell response rendering it an attractive therapy to combine with PD-1/PD-L1 inhibitors. Preclinical data support the rational combination of the 2 modalities and has paved way for the clinical development of the combination across a spectrum of cancers. In this review, we highlight the preclinical and clinical development of combined RT and PD-1/PD-L1 blockade to date. In addition to a comprehensive evaluation of available safety and efficacy data, we discuss important points of consideration in clinical trial design for this promising combination.
ISSN:2051-1426
2051-1426
DOI:10.1186/s40425-018-0361-7